Brilliant Blue G Free Acid

drug
On this page

Summary

Brilliant Blue G Free Acid (CHEMBL4301898) is an approved small molecule.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4301898
NameBrilliant Blue G Free Acid
TypeSmall molecule
Max phase4

Parent form; salt/anhydrous children: CHEMBL4173394

Patent coverage: 1 distinct patent families (1 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Albumin.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ALB6.5Kd320nMCHEMBL_ACT_29180029

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.